Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis

Description:
This technology relates to the discovery and development of a practical, scalable, and commercially viable method for the synthesis of the novel antifungal VT-1129. Cryptococcal meningitis (CM) is a fungal infection that is particularly prevalent in immune-compromised patients and can be treated by VT-1129. CM has a current estimated patient population of 1-1.25 million, predominately in sub-Saharan Africa and the developing world. Several deficiencies and difficulties preclude large-scale preparation and manufacturing with previous processes, which include high cost and potential safety issues. The method described in this invention enables the practical and economical synthesis of VT-1129 at a large scale.
Patent Information:
For Information, Contact:
Suryanarayana Vepa
Technology Licensing Specialist
NIH Technology Transfer
301-827-7181
sury.vepa@nih.gov
Inventors:
Mark Behnke
Scott David
Douglas Fry
William Hoekstra
Christopher Yates
Asaf Alimardanov
Keywords:
Acid
Alcohol
Aminoalcohols
Benzenesulfonic
BSA.
Co-crystal
Containing
Derivatives
Enantioenriched
Fragment
Including
Listed LPM Nguyen-Antczak as of 4/15/2015
Post LPM Assignment Set 20150420
Pre LPM working set 20150418
PROCESS
Synthesis
Tertiary
THOSE
VEXXXX
VT-1129
WMXXXX
© 2024. All Rights Reserved. Powered by Inteum